Gilead to snap up liv­er dis­ease biotech CymaBay for $4.3B

Gilead is bet­ting $4.3 bil­lion on a biotech six months be­fore the FDA is ex­pect­ed to make an ap­proval de­ci­sion on its rare liv­er dis­ease drug can­di­date.

The Cal­i­for­nia big biotech will pay cash to buy CymaBay Ther­a­peu­tics, the com­pa­nies said Mon­day morn­ing. The deal is for $32.50 per share, a 27% pre­mi­um to the biotech’s clos­ing price on Fri­day.

CymaBay’s se­ladel­par cleared its Phase III test in pa­tients with pri­ma­ry bil­iary cholan­gi­tis last Sep­tem­ber, and the FDA set an ap­proval de­ci­sion dead­line of Aug. 14. The rare chron­ic dis­ease main­ly im­pacts women, about 130,000 in the US, ac­cord­ing to Gilead. PBC de­rails liv­er func­tion, with itch­ing and fa­tigue as ear­ly signs.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER